Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology
Group Leader

Sonya Reid

Sonya Reid
Assistant Professor

Dr. Reid is an Assistant Professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center (Vanderbilt Ingram Cancer Center). Her research primarily focuses on health disparities in breast cancer, young-onset breast cancer, and hereditary breast cancer. Specifically, she is investigating genomic differences that may be contributing to the racial survival disparity in breast cancer. Dr. Reid is also focused on improving health care delivery to underserved communities and increasing the representation of minority patients in clinical trials. Dr. Reid received the Martin Luther King Jr. award in recognition of her work in diversity, inclusion, and equity at Vanderbilt University Medical Center. Clinically, she focuses on caring for breast cancer patients with a special interest in high-risk patients.

 

Group Co-Leader

Jessica Sharpe

Vanderbilt University Medical Center

Jessica Sharpe is a third-year oncology fellow at Vanderbilt University Medical Center and will be joining the faculty at Vanderbilt as an Assistant Professor in the breast oncology group in July this year. She has an interest in immunotherapy and its uses in breast cancer as well as toxicities related to immunotherapy. She is also interested in novel treatment combinations to improve care and outcomes for breast cancer patients and is involved in several clinical trials at Vanderbilt.